TARS FY 2021 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$57M

Gross Profit

$55M96.4% margin

Operating Income

-$12M-21.3% margin

Net Income

-$14M-24.2% margin

EPS (Diluted)

$-0.67

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

$3M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$179M

Total Liabilities

$12M

Stockholders' Equity

$167M

Cash & Equivalents

$171M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$57M	$0	—
Gross Profit	$55M	-$246,000	+22438.2%
Operating Income	-$12M	-$27M	+54.9%
Net Income	-$14M	-$27M	+48.4%